MX354215B - Inhibidores de la proteina 90 de choque termico (hsp90). - Google Patents
Inhibidores de la proteina 90 de choque termico (hsp90).Info
- Publication number
- MX354215B MX354215B MX2013011531A MX2013011531A MX354215B MX 354215 B MX354215 B MX 354215B MX 2013011531 A MX2013011531 A MX 2013011531A MX 2013011531 A MX2013011531 A MX 2013011531A MX 354215 B MX354215 B MX 354215B
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- pharmaceutically acceptable
- independently
- compound
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La descripción se refiere a compuestos de la fórmula (1) y sales farmacéuticamente aceptables de los mismos, en donde (a) cada uno de Z1, Z2 y Z3 es independientemente CH o N; (b) Y es S; (c) Xa y Xb son O; Cd) Xc es -CH; (e) X2 es -NR1R2, en donde R1 y R2 son cada uno independientemente H, C1-C6 alquilo, C2-C6 alquenilo, C2-C6 alquinilo, cicloalquilo, heteroalquilo, heterocicloalquilo, arilo, heteroarilo, alquilarilo, arilalquilo, heteroarilo, heteroarilalquilo, o alquilheteroarilalquilo; (f) X4 es hidrógeno o halógeno; y (g) R es R10-NH-R11 en donde R10 es etileno o propileno, y R11 es un alquilo ramificado. Composiciones que comprenden una cantidad efectiva de un compuesto de la Fórmula (1) o una sal farmacéuticamente aceptable del mismo y métodos para tratar y prevenir una condición, tal como cáncer que sobreexpresa Her-cinasas, que comprende administrar a un paciente en necesidad de lo mismo una cantidad terapéuticamente efectiva de un compuesto de la Fórmula (1) o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161472061P | 2011-04-05 | 2011-04-05 | |
PCT/US2012/032373 WO2012138896A1 (en) | 2011-04-05 | 2012-04-05 | Hsp90 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013011531A MX2013011531A (es) | 2014-08-22 |
MX354215B true MX354215B (es) | 2018-02-19 |
Family
ID=46018086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013011531A MX354215B (es) | 2011-04-05 | 2012-04-05 | Inhibidores de la proteina 90 de choque termico (hsp90). |
Country Status (12)
Country | Link |
---|---|
US (2) | US9546170B2 (es) |
EP (1) | EP2694506B1 (es) |
JP (1) | JP5961683B2 (es) |
KR (1) | KR101984480B1 (es) |
CN (1) | CN103596955B (es) |
AU (1) | AU2012240079B2 (es) |
BR (1) | BR112013025761A2 (es) |
CA (1) | CA2832099C (es) |
EA (1) | EA024647B1 (es) |
ES (1) | ES2647889T3 (es) |
MX (1) | MX354215B (es) |
WO (1) | WO2012138896A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
EP2034839B1 (en) | 2006-06-30 | 2017-08-23 | Sloan-Kettering Institute for Cancer Research | Treatment of neurodegenerative diseases through inhibition of hsp90 |
JP5941407B2 (ja) | 2009-10-07 | 2016-06-29 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Hsp90阻害剤 |
EP2694505B1 (en) | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
EP2694506B1 (en) | 2011-04-05 | 2017-09-20 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
AU2012282903A1 (en) | 2011-07-08 | 2014-02-13 | Sloan-Kettering Institute For Cancer Research | Uses of labeled HSP90 inhibitors |
KR102124109B1 (ko) | 2012-02-09 | 2020-06-17 | 유니버시티 오브 캔사스 | C말단 hsp90 억제제 |
TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲lrrk2抑制劑的芳基吡咯并吡啶衍生化合物 |
CA2921571C (en) | 2013-08-16 | 2022-04-05 | Memorial Sloan-Kettering Cancer Center | Selective grp94 inhibitors and uses thereof |
BR112016014758A8 (pt) | 2013-12-23 | 2020-06-02 | Memorial Sloan Kettering Cancer Center | composto e método para a marcação radioativa e composição farmacêutica compreendendo o referido composto |
SG11201610677XA (en) * | 2014-06-24 | 2017-01-27 | Univ Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
MX2017003513A (es) | 2014-09-17 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia. |
TW201722422A (zh) | 2015-10-05 | 2017-07-01 | 美國紀念斯隆-凱特琳癌症中心 | 用於治療癌症之合理組合療法 |
IL278698B2 (en) | 2018-05-14 | 2024-06-01 | Reata Pharmaceuticals Inc | Bi-aryl amides with sugar groups that are adapted to the treatment of diseases related to the heat stroke protein pathway |
WO2023006993A1 (en) | 2021-07-30 | 2023-02-02 | Atmosr | Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE460423T1 (de) | 1997-05-14 | 2010-03-15 | Sloan Kettering Inst Cancer | Verfahren und zubereitungen zur zerstörung bestimmter proteine |
EP1169319A4 (en) | 1999-04-09 | 2005-02-09 | Sloan Kettering Institutefor C | METHODS AND COMPOSITIONS FOR DEGRADING AND / OR INHIBITING TYROSINE KINASES BELONGING TO THE HER FAMILY |
US7439359B2 (en) | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
JP2005505506A (ja) * | 2001-06-12 | 2005-02-24 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用な大環状分子 |
AU2002343604C1 (en) | 2001-10-30 | 2009-09-17 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
AU2002356922A1 (en) | 2001-11-09 | 2003-05-26 | Conforma Therapeutics Corporation | Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
CN1649866A (zh) | 2002-02-28 | 2005-08-03 | 阿斯特拉曾尼卡有限公司 | 3-环状基-5-(含氮5-元环)甲基-噁唑烷酮衍生物及其作为抗菌药物的用途 |
WO2004094647A2 (en) | 2003-04-18 | 2004-11-04 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
BRPI0414533A (pt) | 2003-09-18 | 2006-11-07 | Conforma Therapeutics Corp | composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90 |
US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
JP5226513B2 (ja) | 2005-08-26 | 2013-07-03 | メルク セローノ ソシエテ アノニム | ピラジン誘導体及びその使用 |
CA2634723A1 (en) | 2005-12-22 | 2007-07-05 | Conforma Therapeutics Corporation | Orally active purine-based inhibitors of heat shock protein 90 |
CN101490052B (zh) | 2006-05-12 | 2012-08-08 | 美瑞德生物工程公司 | 治疗性化合物及其在癌症中的用途 |
EP2034839B1 (en) | 2006-06-30 | 2017-08-23 | Sloan-Kettering Institute for Cancer Research | Treatment of neurodegenerative diseases through inhibition of hsp90 |
US20080221132A1 (en) | 2006-09-11 | 2008-09-11 | Xiong Cai | Multi-Functional Small Molecules as Anti-Proliferative Agents |
FR2906824B1 (fr) | 2006-10-09 | 2008-12-26 | Roger Mondelin Sas Soc Par Act | Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques |
CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
MY148860A (en) * | 2007-03-20 | 2013-06-14 | Curis Inc | Fused amino pyridine as hsp90 inhibitors |
US20080234297A1 (en) | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
US20100240656A1 (en) | 2007-07-12 | 2010-09-23 | Oryzon Genomics, S.A. | Compounds as hsp90 inhibitors |
WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
EP2219448A4 (en) | 2007-11-14 | 2011-10-12 | Myriad Pharmaceuticals Inc | THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS |
NZ594414A (en) | 2009-01-16 | 2013-08-30 | Curis Inc | Fused amino pyridines for the treatment of brain tumors |
JP5941407B2 (ja) | 2009-10-07 | 2016-06-29 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Hsp90阻害剤 |
EP2694505B1 (en) | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
EP2694506B1 (en) | 2011-04-05 | 2017-09-20 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
CA2921571C (en) | 2013-08-16 | 2022-04-05 | Memorial Sloan-Kettering Cancer Center | Selective grp94 inhibitors and uses thereof |
-
2012
- 2012-04-05 EP EP12717521.4A patent/EP2694506B1/en active Active
- 2012-04-05 BR BR112013025761A patent/BR112013025761A2/pt not_active IP Right Cessation
- 2012-04-05 KR KR1020137029258A patent/KR101984480B1/ko active IP Right Grant
- 2012-04-05 CN CN201280027360.XA patent/CN103596955B/zh not_active Expired - Fee Related
- 2012-04-05 CA CA2832099A patent/CA2832099C/en active Active
- 2012-04-05 AU AU2012240079A patent/AU2012240079B2/en not_active Ceased
- 2012-04-05 JP JP2014503996A patent/JP5961683B2/ja not_active Expired - Fee Related
- 2012-04-05 EA EA201391337A patent/EA024647B1/ru not_active IP Right Cessation
- 2012-04-05 US US14/110,095 patent/US9546170B2/en active Active
- 2012-04-05 MX MX2013011531A patent/MX354215B/es active IP Right Grant
- 2012-04-05 ES ES12717521.4T patent/ES2647889T3/es active Active
- 2012-04-05 WO PCT/US2012/032373 patent/WO2012138896A1/en active Application Filing
-
2016
- 2016-12-09 US US15/374,007 patent/US10064867B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN103596955B (zh) | 2016-11-16 |
NZ616890A (en) | 2016-01-29 |
US20170151247A1 (en) | 2017-06-01 |
US9546170B2 (en) | 2017-01-17 |
EA201391337A1 (ru) | 2014-05-30 |
WO2012138896A1 (en) | 2012-10-11 |
EP2694506B1 (en) | 2017-09-20 |
US10064867B2 (en) | 2018-09-04 |
BR112013025761A2 (pt) | 2018-05-29 |
MX2013011531A (es) | 2014-08-22 |
KR20140073464A (ko) | 2014-06-16 |
CA2832099C (en) | 2019-07-09 |
JP5961683B2 (ja) | 2016-08-02 |
EP2694506A1 (en) | 2014-02-12 |
KR101984480B1 (ko) | 2019-05-31 |
US20140045867A1 (en) | 2014-02-13 |
ES2647889T3 (es) | 2017-12-27 |
EA024647B1 (ru) | 2016-10-31 |
CA2832099A1 (en) | 2012-10-11 |
AU2012240079A1 (en) | 2013-11-07 |
CN103596955A (zh) | 2014-02-19 |
JP2014510149A (ja) | 2014-04-24 |
AU2012240079B2 (en) | 2017-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013011531A (es) | Inhibidores de la proteina 90 de choque termico (hsp90). | |
MX2013011532A (es) | Inhibidores de la proteina 90 de choque termico (hsp90). | |
NZ603155A (en) | Phospholipid drug analogs | |
MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
JP2014510149A5 (es) | ||
CR20140301A (es) | Derivados de betulina | |
TN2015000121A1 (en) | Gdf-8 inhibitors | |
PH12015502675A1 (en) | Cycloaklane derivative | |
MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
TN2015000102A1 (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors | |
DOP2014000058A (es) | 3- pirmidin- 4- il- oxazolidin- 2- onas como inhibidores de la idh mutante | |
MX2010007375A (es) | Nuevos derivados de lupano. | |
TN2012000401A1 (en) | Heterocyclic compound | |
MY172924A (en) | Neprilysin inhibitors | |
MX2013003019A (es) | Compuestos de azabenzotiazol, composiciones y metodos de uso. | |
MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
EA201170617A1 (ru) | Пиразолиламинопиридины в качестве ингибиторов fak | |
WO2014078295A8 (en) | Gemcitabine prodrugs and uses thereof | |
MX2013005508A (es) | Compuestos de lipoilo y su uso para tratar lesion isquemica. | |
IN2014CN04449A (es) | ||
PH12016500838A1 (en) | Isoxazolines as therapeutic agents | |
MX2013007938A (es) | Compuesto biciclico novedoso o sal del mismo. | |
NZ712660A (en) | Dicarboxylic acid compound | |
MY176727A (en) | Selective androgen receptor modulators | |
MX2013002620A (es) | Novedosas n-hidroxi-benzamidas para el tratamiento del cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |